Written and maintained by CASRAI Editorial Board
Last updated
This page describes laboratory biomarkers, estimating equations, and clinical evaluation methods; it is not individual medical advice.
Short Answer
Cystatin C eGFR is an estimate of glomerular filtration rate calculated from serum cystatin C, a low-molecular-weight protease inhibitor produced constantly by all nucleated cells. Unlike serum creatinine, cystatin C is independent of muscle mass and dietary protein. It serves as an essential confirmatory biomarker for chronic kidney disease, particularly when creatinine-based estimates are borderline or misleading.
Definition and Scope
Glomerular filtration rate (GFR) quantifies the volume of plasma filtered through glomerular capillaries per unit of time, normalized to body surface area (mL/min/1.73 m²). Direct measurement with exogenous clearance tracers (iohexol or inulin) is the reference standard but impractical for routine care. Clinical nephrology and laboratory medicine instead rely on endogenous filtration markers to estimate GFR (eGFR).
Cystatin C is a 13-kDa basic, non-glycosylated protein of 120 amino acids produced constitutively across all nucleated cells. When utilized as an in vitro diagnostic marker, circulating cystatin C reflects glomerular filtration capacity. To ensure measurement comparability across assay manufacturers, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the European Commission Joint Research Centre developed certified reference material ERM-DA471/IFCC, harmonizing assay calibration on automated analyzers worldwide.
How It Works or How It Is Used in Practice
Cystatin C is synthesized at a constant rate and freely filtered across the glomerular filtration barrier. In the renal tubule, it is reabsorbed and catabolized by proximal tubular epithelial cells via megalin-mediated endocytosis, with negligible return to circulation and no active tubular secretion. In contrast, serum creatinine undergoes 10% to 20% active proximal tubular secretion, which increases unpredictably as renal function declines.
Laboratories measure serum cystatin C using automated particle-enhanced turbidimetric immunoassays (PETIA) or nephelometric immunoassays (PENIA) calibrated to ERM-DA471/IFCC. Concentrations are entered into validated mathematical formulas. In modern nephrology research and clinical practice, the accepted standard is the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations published by Inker and colleagues in the New England Journal of Medicine:
- 2021 CKD-EPI Creatinine Equation (eGFRcr): Refitted without race coefficients using serum creatinine, age, and sex.
- 2021 CKD-EPI Cystatin C Equation (eGFRcys): Evaluates GFR from serum cystatin C, age, and sex without a race variable.
- 2021 CKD-EPI Combined Creatinine-Cystatin C Equation (eGFRcr-cys): Combines both filtration markers with age and sex without race variables.
In the CKD-EPI validation cohort of 4,050 participants across 12 studies, combined eGFRcr-cys achieved 91.0% P30 accuracy (89.5% Black, 91.2% non-Black), outperforming eGFRcr alone (86.5% to 87.2%) by averaging out independent marker variations.
Types or Related Concepts
The table below summarizes biological characteristics, clearance pathways, non-GFR determinants, and validation accuracy across primary filtration assessment methods.
| Assessment Method | Biomarker Nature | Renal Clearance Mechanism | Major Non-GFR Determinants | Validation Accuracy (P30) | Primary Clinical Application |
|---|---|---|---|---|---|
| Serum Creatinine (eGFRcr) | 113-Da muscle metabolite | Filtration plus 10% to 20% tubular secretion | Muscle mass, meat intake, frailty, amputation, cirrhosis | 86.5% to 87.2% within 30% of mGFR (Inker et al. 2021) | Initial screening in ambulatory patients with stable muscle bulk |
| Serum Cystatin C (eGFRcys) | 13-kDa cellular protein | Filtration; tubular reabsorption and catabolism; zero secretion | Hyperthyroidism, hypothyroidism, high-dose corticosteroids | 86.0% to 88.0% within 30% of mGFR (Inker et al. 2021) | Alternative when creatinine is distorted by muscle wasting or cirrhosis |
| Combined Dual-Marker (eGFRcr-cys) | Dual-marker model integrating metabolite and cellular protein | Combines filtration profiles; reciprocal balancing reduces marker bias | Attenuates non-GFR determinants of each individual marker | 91.0% within 30% of mGFR; 89.5% Black, 91.2% non-Black (Inker et al. 2021) | Confirmatory testing for eGFR 45 to 59 mL/min/1.73 m²; drug clearance |
| Measured GFR (mGFR) | Exogenous tracers (iohexol, inulin) | Glomerular filtration only; zero tubular handling | None (direct physiological reference measurement) | 100% concordance by physiological definition | Living kidney donor evaluation; pharmacokinetic protocols |
These assessment methods inform diagnostic pathways spanning clinical disciplines, including distinctions between nephrology and urology. Endogenous marker evaluation also follows diagnostic principles under the FDA Biomarker Qualification Program.
Where It Matters for Labs, Clinics or Supply Decisions
The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline and the National Kidney Foundation and American Society of Nephrology (NKF-ASN) Task Force recommend cystatin C in specific clinical contexts:
- Confirmatory Staging in Borderline CKD (Stage 3a): Recommended when initial eGFRcr is 45 to 59 mL/min/1.73 m² without albuminuria. Confirming eGFR ≥60 mL/min/1.73 m² reclassifies up to one-third of individuals as non-CKD.
- Atypical Muscle Mass: In patients with severe sarcopenia, frailty, paraplegia, or limb amputations, low creatinine generation masks renal impairment. Conversely, bodybuilders show falsely elevated creatinine. Cystatin C provides an unbiased, muscle-independent estimate.
- Advanced Liver Cirrhosis: Blunted hepatic creatine synthesis and sarcopenia cause creatinine to overestimate GFR in cirrhosis. Cystatin C reflects filtration without hepatic synthesis confounding.
- Narrow-Therapeutic-Index Dosing: High-precision GFR estimation is essential when dosing toxic medications cleared primarily by filtration (platinum chemotherapy, aminoglycosides, vancomycin, DOACs). Combined eGFRcr-cys improves dosing safety.
- Living Kidney Donor Screening: Prospective donors require verified baseline renal function to ensure safety before nephrectomy.
- Clinical Trials and Acute Monitoring: Cystatin C provides a stable endpoint when muscle mass fluctuates. In acute care, filtration markers are interpreted alongside protocols for how to measure urine output.
Common Misunderstandings
- Belief that cystatin C is completely free of non-renal determinants: While independent of muscle mass and diet, cystatin C is influenced by thyroid status. Hyperthyroidism accelerates metabolism and CST3 transcription, elevating serum cystatin C and falsely lowering eGFRcys. Hypothyroidism decreases cystatin C production, falsely elevating eGFRcys. High-dose systemic corticosteroids also stimulate CST3 transcription.
- Assuming cystatin C should replace creatinine for all routine screening: Serum creatinine remains the primary first-line screening test due to lower reagent cost and universal availability on routine panels. Cystatin C serves as a selective confirmatory tool.
- Belief that cystatin C requires race adjustments: Cystatin C does not correlate with race, and the 2021 CKD-EPI equations eliminated race coefficients entirely across all formulas.
- Misunderstanding tubular handling: Because cystatin C is catabolized within proximal tubular cells after filtration rather than excreted intact, 24-hour urine collection of cystatin C is not clinically useful for measuring GFR.
Frequently Asked Questions
What is the difference between creatinine eGFR and cystatin C eGFR?
Creatinine eGFR is calculated from serum creatinine, a muscle metabolite influenced by muscle bulk, diet, and tubular secretion. Cystatin C eGFR uses serum cystatin C, a cellular protein produced constantly across nucleated cells that is independent of muscle mass and cleared by filtration without tubular secretion.
When should clinicians order a cystatin C eGFR test?
Under KDIGO 2024 guidelines, cystatin C or combined eGFRcr-cys is recommended when creatinine eGFR is 45 to 59 mL/min/1.73 m² without albuminuria, in individuals with abnormal muscle mass (amputees, bodybuilders, sarcopenia), in liver cirrhosis, or during living kidney donor evaluations.
How does thyroid disease affect cystatin C eGFR results?
Thyroid status alters cellular cystatin C production. Hyperthyroidism increases CST3 expression, elevating serum cystatin C and falsely lowering eGFRcys. Hypothyroidism reduces production, lowering serum cystatin C and falsely elevating eGFRcys. Clinicians should interpret results cautiously during active thyroid disease.
Why is the combined creatinine-cystatin C equation preferred for confirmatory testing?
In the 2021 CKD-EPI validation studies by Inker and colleagues, combining creatinine and cystatin C achieved a P30 accuracy of 91.0%, outperforming creatinine alone (86.5% to 87.2%) and cystatin C alone (86.0% to 88.0%) by balancing out independent non-GFR confounders.
Does a cystatin C blood test require fasting or a 24-hour urine collection?
No. Serum cystatin C is measured from a standard blood draw and does not require fasting or urine collection. Because cystatin C is catabolized inside proximal tubular cells rather than excreted intact, urinary measurements cannot evaluate filtration.
Sources
- Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. New England Journal of Medicine. 2021; 385(19): 1737-1749. DOI: 10.1056/NEJMoa2102953. URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2102953
- KDIGO CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024; 105(4S): S117–S314. DOI: 10.1016/j.kint.2023.10.018. URL: https://kdigo.org/guidelines/ckd-evaluation-and-management/
- Grubb A, Blirup-Jensen S, Lindström V, et al. First certified reference material for cystatin C in human serum: ERM-DA471/IFCC. Clinical Chemistry and Laboratory Medicine. 2010; 48(11): 1619-1621. DOI: 10.1515/CCLM.2010.318. PMID: 21034257. URL: https://pubmed.ncbi.nlm.nih.gov/21034257/
- Delgado C, Baigent C, Bello AK, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases. American Journal of Kidney Diseases. 2022; 79(2): 268-288.e1. DOI: 10.1053/j.ajkd.2021.09.004. PMID: 34563508. URL: https://www.kidney.org/professionals/kdoqi/gfr_calculator/nkf-asn-task-force
